The vaccine is being modified to target early omicron variants, but newer variants are gaining dominance.īecause the virus keeps mutating and will be around for a long time, the market for Pfizer’s products won’t go away. At $30.47 a dose, it’s a significant premium over the $19.50-a-dose rate the government paid for the first 100 million. Just last week, the Biden administration agreed to buy another 105 million doses of Pfizer’s covid vaccine for the fall booster campaign, paying $3.2 billion. “Then you have the treatment that will, let’s say, resolve the issues of those that are getting the disease.” “Hopefully, we could be giving it annually and maybe for some groups that are high-risk more often,” CEO Albert Bourla told investors this year. Yet, while patients may recoil at the need for repeated injections - two boosters are now recommended for people 50 and older - the requirement is gold for investors. Paxlovid’s value to vaccinated patients isn’t yet clear, and Pfizer’s covid vaccine doesn’t entirely prevent infections, although each booster temporarily restores some protection. In Cambridge, Mass.Subscribe to KFF Health News' free Weekly Edition. From Ireland to India, from South Africa to the England, activists took to the streets to call on these companies to share the technology. Activists speak outĪll three pharmaceutical companies conducted shareholder meetings on April 28th, and on the same day, civil society organizations and members of the People’s Vaccine Alliance held rallies and demonstrations to call attention to the need for expanded vaccine production. Johnson & Johnson released its resolution vote result over the following weekend, and reported 34 percent of shareholders supported Oxfam’s resolution. “We believe this strong vote share demonstrates that a significant number of Moderna and Pfizer’s shareholders recognize that the only sustainable way to end the pandemic is to leverage the world’s full manufacturing capacity as quickly as possible,” said Oxfam’s Robert Silverman in a statement. The shareholder resolutions at Moderna and Pfizer received nearly 30 percent support among independent shareholders. Two influential institutional shareholder advisers recommended support for Oxfam’s resolutions, with one acknowledging global demand for vaccine equity amid criticism of the companies’ alleged prioritization of profits, as well as support for a temporary waiver of intellectual property rules at the World Trade Organization. In India alone, over two million children have lost a parent to the pandemic. “Millions of grandparents and healthcare workers across Africa are not protected from this virus. “This injustice has heartbreaking consequences,” she said. Maaza Seyoum, the Global South convener for the People’s Vaccine Alliance, presented the resolution saying that the company had not done enough to ensure equitable access to its vaccine despite receiving an estimated $1.5 billion in public funds. “But instead of continuing to work together to end the pandemic, Pfizer has chosen to turn its back on the world."Ī third Oxfam resolution to Johnson & Johnson sought clarification on how the public support that the company received factors into its vaccine prices. “The vaccine was made possible by public taxpayer funding and contributions from the global, scientific community,” Barkan said to shareholders at Pfizer’s annual meeting. Oxfam submitted a similar resolution to Pfizer shareholders it was presented by Ady Barkan, the founder and co-director of Be A Hero.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |